The Cyprus Foundation For Muscular Dystrophy Research
- Address
- lock Available on a paid plan
Neuromuscular and Amyloidosis Research
At the Cyprus Foundation For Muscular Dystrophy Research, clinical trials in nervous system diseases and musculoskeletal diseases focus on conditions that affect muscle strength, nerve function, and mobility. The main diseases under study include hereditary transthyretin amyloidosis, hereditary transthyretin-mediated amyloid polyneuropathy, and active idiopathic inflammatory myopathy, with research aimed at testing new treatments and understanding their impact on neurological and functional outcomes.
- Hereditary transthyretin amyloidosis and related polyneuropathy
- Active idiopathic inflammatory myopathy
- Evaluating treatment effectiveness and safety in nerve and muscle disorders
This work reflects a strong interest in improving care for inherited and inflammatory conditions that can progressively affect daily function.
Myasthenia Gravis Studies
Research in immune system diseases at this site includes studies of acetylcholine receptor binding antibody seronegative generalized myasthenia gravis and ocular myasthenia gravis. These trials are designed to assess whether new therapies can reduce muscle weakness and improve symptom control in people living with these autoimmune disorders.
- Acetylcholine receptor binding antibody seronegative generalized myasthenia gravis
- Ocular myasthenia gravis
- Testing therapies that may improve disease control and patient function
The EMG Laboratory and neuromuscular expertise support research into disorders where communication between nerves and muscles is disrupted.
Hereditary Transthyretin Amyloidosis Programs
Several trials at this hospital and clinic research site concentrate on congenital and hereditary diseases, especially hereditary transthyretin-mediated amyloidosis and its neuropathic forms. The goal is to evaluate whether emerging treatments can slow nerve damage, preserve function, and improve the overall course of this inherited condition.
- Hereditary transthyretin-mediated amyloidosis with polyneuropathy
- Hereditary transthyretin amyloidosis
- Assessing neurologic benefit and long-term treatment safety
These studies are especially relevant for patients with progressive inherited disease affecting the peripheral nerves.
Inflammatory Muscle Disease Research
Clinical research also extends to immune-mediated muscle disorders, including active idiopathic inflammatory myopathy. The trials in this area are focused on determining whether investigational therapies can improve clinical signs, reduce disease activity, and support better outcomes for adults with inflammatory muscle involvement.
- Active idiopathic inflammatory myopathy
- Improving symptoms and functional response in inflammatory muscle disease
- Exploring new options for immune-related muscle weakness
This area complements the site’s broader expertise in muscular dystrophy research and neuromuscular care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Argenx4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 4 other sites in Cyprus
Therapeutic Area Benchmark — Cyprus
Select a therapeutic area to compare against other sites in Cyprus.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Cyprus
Market Share
Country: Cyprus
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in The Cyprus Foundation For Muscular Dystrophy Research
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | Argenx | Phase III | Not Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Efgartigimod Alfa | 4 | Unknown | 2023-03-01 | 2025-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.